There is an urgent need to develop novel therapies for patients with anorexia nervosa (AN). A condition that is heterogeneous, highly resistant to treatment, and associated with striking rates of morbidity and mortality, few therapeutic advances specifically for AN have been made in the past 150 years. A re-orientation in the last two decades toward neuroscientific explanations for AN offers hope that an increased understanding of the illness’ neural roots will lead to better treatments (Kaye et al, 2009).
Deep brain stimulation (DBS) is a neurosurgical procedure that targets critical nodes in dysfunctional neural circuits driving pathological behaviors (Lozano and Lipsman, 2013; Mayberg et al, 2005). DBS’ efficacy in disorders like Parkinson’s Disease has driven its investigation in other circuit-based conditions, including major depression (Lozano and Lipsman, 2013). Several factors led us to consider DBS in refractory AN. First, the primarily limbic structures implicated in the disorder, largely by functional neuroimaging, are consistent with the clinical observations that AN is predominantly a disorder of emotional processing. Further, the ability of DBS to safely and effectively access limbic nodes in mood- and anxiety-related circuits suggested that it could be applied to AN, a disorder marked by high rates of depressed mood and affective dysregulation.
The subcallosal cingulate (SCC) has a key role in modulating emotional states and projects cortically, to medial- and orbitofrontal cortex, as well as subcortically to nucleus accumbens. Our group has also shown that SCC neurons participate directly in emotion processing, responding preferentially to affective-laden stimuli and decisions (Lipsman et al, 2013a). The SCC is thus both structurally and functionally integrated into emotion pathways, and its activity linked to disorders of emotion.
Our initial experience in a small group of treatment-refractory patients (N=6; average age: 38 years; average illness duration: 18 years) showed DBS to be reasonably safe in AN, and associated with improvements in comorbid mood and anxiety symptoms (Lipsman et al, 2013b). These results were maintained during 6 months of clinical follow-up, with significant reductions in depressed mood and anxiety translating, over time, into increases in BMI (Figure 1). Although time spent on eating- and weight-related preoccupations and rituals did decrease (Lipsman et al, 2013b), we believe the primary effect of DBS was an improved utilization of conventional AN treatment as a result of improved mood and affective regulation.
The influence of focal stimulation on global cerebral metabolism can be investigated with functional imaging, such as positron emission tomography (PET; Figure 2). PET studies in both AN and depression patients have shown significant network-wide changes in glucose utilization with DBS of the SCC. For example, after 6 months of DBS, both patient groups see significant activity reductions in the SCC and insula, as well as significant activity increases in the parietal lobe (Lipsman et al, 2013b; Mayberg et al, 2005). In AN, this change in parietal activity constitutes an effective reversal of known baseline parietal hypometabolism seen in acutely ill AN patients (Delvenne et al, 1996). These results confirm that although DBS is a focal, targeted therapy, it can influence metabolism in remote regions, and that AN-relevant structures, such as those governing mood, emotion regulation, and body perception, can be modulated by SCC stimulation.
Determining the potential role of DBS in the AN treatment algorithm will await the results of larger, sham-stimulation trials. It is clear, however, that the condition’s physical and emotional symptoms are inextricably linked, and novel treatment strategies will need to address both in equal measure, to offer patients hope for a meaningful and enduring recovery.
FUNDING AND DISCLOSURE
NL declares no conflict of interest. AML is a consultant for St Jude Medical, Medtronic and Boston Scientific, and holds intellectual property related to brain stimulation for depression.
References
Delvenne V, Goldman S, De Maertelaer V, Simon Y, Luxen A, Lotstra F (1996). Brain hypometabolism of glucose in anorexia nervosa: normalization after weight gain. Biol Psychiatry 40: 761–768.
Kaye WH, Fudge JL, Paulus M (2009). New insights into symptoms and neurocircuit function of anorexia nervosa. Nat Rev Neurosci 10: 573–584.
Lipsman N, Kaping D, Westendorff S, Sankar T, Lozano AM, Womelsdorf T (2013a). Beta coherence within human ventromedial prefrontal cortex precedes affective value choices. NeuroImage S1053-8119: 00607–1.
Lipsman N, Woodside DB, Giacobbe P, Hamani C, Carter JC, Norwood SJ et al (2013b). Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet 381: 1361–1370.
Lozano AM, Lipsman N (2013). Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 77: 406–424.
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C et al (2005). Deep brain stimulation for treatment-resistant depression. Neuron 45: 651–660.
Acknowledgements
The trial described was made possible by a grant from the Klarman Family Foundation Grants Program in Eating Disorders Research and by a Fellowship to NL from the Canadian Institutes of Health Research (CIHR).
Author information
Authors and Affiliations
Corresponding author
PowerPoint slides
Rights and permissions
About this article
Cite this article
Lipsman, N., Lozano, A. Targeting Emotion Circuits with Deep Brain Stimulation in Refractory Anorexia Nervosa. Neuropsychopharmacol 39, 250–251 (2014). https://doi.org/10.1038/npp.2013.244
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2013.244
This article is cited by
-
Brainjacking in deep brain stimulation and autonomy
Ethics and Information Technology (2018)
-
The Ethics of Deep Brain Stimulation for the Treatment of Anorexia Nervosa
Neuroethics (2015)